【摘要】 目的探讨碳青霉烯类耐药的铜绿假单胞菌和鲍曼不动杆菌的临床分布及耐药特性,为临床抗感染治疗和合理使用抗生素提供依据。方法采用微量肉汤稀释法测定12种抗菌药物的最低抑菌浓度(MIC)。结果两年共分离碳青霉烯类耐药的铜绿假单胞菌和鲍曼不动杆菌分别为261株、117株,两者80%以上来源于呼吸道标本,41%碳青霉烯类耐药的铜绿假单胞菌和64.9%碳青霉烯类耐药鲍曼不动杆菌来自于重症监护病房。碳青霉烯类耐药鲍曼不动杆菌的多重耐药性比铜绿假单胞菌更为严重,此菌株除头孢哌酮/舒巴坦耐药率在23.4%外,其他均在70%以上,亚胺培南和美罗培南耐药率分别为92.8%和96.4%。相反,碳青霉烯类耐药的铜绿假单胞菌对亚胺培南和美罗培南耐药情况却差异较大,16%菌株对亚胺培南耐药,而对美罗培南敏感,其中可能存在不同的耐药机理。结论碳青霉烯类耐药的铜绿假单胞菌和鲍曼不动杆菌的耐药率在不断上升,特别是多重耐药和泛耐药株的增多。因此,应慎重、合理地使用碳青霉烯类抗菌药药物,密切关注铜绿假单胞菌和鲍曼不动杆菌耐药的发展,采取有效的感染控制措施。更多还原

【Abstract】 【Objective】 To investigate the clinical characteristics of distribution and drug resistance of carbapenem-resistant Psedomonas aeruginosa and Acinetobacter baumannii.【Methods】 Both microdilution method was made to determine the minimum inhibitory concentration(MIC) of 261 isolated carbapenem-resistant Psedomonas aeruginosa and 117 isolated Acinetobacter baumannii.【Results】 Separation of two years,carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii,respectively 261,117,both more than 80% from respiratory tract specimens,41% of the carbapenem-resistant Pseudomonas aeruginosa intracellular bacteria and 64.9% of carbapenem-resistant Acinetobacter baumannii from the intensive care ward,carbapenem-resistant Acinetobacter baumannii in multi-drug resistance than the carbapenem-resistant Pseudomonas aeruginosa is more seriously,this strain except cefoperazone/sulbactam resistance rates of 23.4%,while the rest were above 70%,imipenem and meropenem resistance rates were 92.8% and 96.4%.Carbapenem-resistant Pseudomonas aeruginosa resistant to imipenem and meropenem situation is quite different,16% of strains resistant to imipenem,while meropenem-sensitive,which may have different mechanisms of drug resistance.【Conclusion】 Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii resistance rates on the rise,especially in multi-drug resistance and pan-resistant strains has increased.So be careful,rational use of carbapenem antibacterial drugs,pay close attention to Pseudomonas aeruginosa and Acinetobacter baumannii resistant to the development of effective infection control measures.更多还原